Business
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include:
About this update from Aditxt, Inc.
[{"type":"text","content":"-- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter --","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"-- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt -- ","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include:","length":307,"tagName":"p"},{"type":"image","alt":"Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Women's health innovator Evofem Biosciences (OTCQB: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/b0b393f2cbffee7b6c52a7dea7c44bd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s3aOPVcdo91_a65mo20iIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b0b393f2cbffee7b6c52a7dea7c44bd2","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"list","items":[{"val":[{"type":"text","content":"Delivered $4.8 million in net sales of in the second quarter of 2025 compared to $4.2 million in the prior year quarter.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Improved loss from operations to $1.3 million compared to $1.4 million in the prior year quarter.","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced strategies to reduce manufacturing costs by approximately 50% for both PHEXXI and SOLOSEC, which are designed to increase per-unit profit and facilitate entry into price-sensitive global markets.","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel was submitted for marketing approval in the United Arab Emirates (UAE) by licensee Pharma 1 Drug Store.","lengt...